Legend Biotech Corp
NASDAQ:LEGN

Watchlist Manager
Legend Biotech Corp Logo
Legend Biotech Corp
NASDAQ:LEGN
Watchlist
Price: 39.75 USD 0.4% Market Closed
Market Cap: 7.3B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+101%
Revenue
Forecast
+15%
Operating Income
Forecast
N/A
Net Income
Forecast
-15%

Wall Street
Price Targets

LEGN Price Targets Summary
Legend Biotech Corp

Wall Street analysts forecast LEGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LEGN is 79.02 USD with a low forecast of 53.65 USD and a high forecast of 99.75 USD.

LEGN Lowest Forecast
Wall Street Target
53.65 USD
35% Upside
LEGN Average Forecast
Wall Street Target
79.02 USD
99% Upside
LEGN Highest Forecast
Wall Street Target
99.75 USD
151% Upside
Lowest
Price Target
53.65 USD
35% Upside
Average
Price Target
79.02 USD
99% Upside
Highest
Price Target
99.75 USD
151% Upside
Legend Biotech Corp Competitors:
Price Targets
B
251120
Bio-FD&C Co Ltd
7% Upside
4587
PeptiDream Inc
121% Upside
ALDX
Aldeyra Therapeutics Inc
71% Upside
CDNA
CareDx Inc
54% Upside
B
251120
Bio-FD&C Co Ltd
7% Upside
4587
PeptiDream Inc
121% Upside
ALDX
Aldeyra Therapeutics Inc
71% Upside
CDNA
CareDx Inc
54% Upside
301080
Acrobiosystems Co Ltd
15% Upside
INSM
Insmed Inc
9% Upside
AMGN
Amgen Inc
7% Upside
VLA
Valneva SE
158% Upside

Revenue
Forecast

Revenue Estimate
Legend Biotech Corp

For the last 6 years the compound annual growth rate for Legend Biotech Corp's revenue is 53%. The projected CAGR for the next 3 years is 51%.

53%
Past Growth
51%
Estimated Growth
Estimates Accuracy
-10%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Legend Biotech Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
14%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Legend Biotech Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

See Also

Summary
LEGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
LEGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LEGN stock valuation using valuation multiples.
Wall Street Estimates
LEGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LEGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LEGN's stock price target?
Price Target
79.02 USD

According to Wall Street analysts, the average 1-year price target for LEGN is 79.02 USD with a low forecast of 53.65 USD and a high forecast of 99.75 USD.

What is Legend Biotech Corp's Revenue forecast?
Projected CAGR
51%

For the last 6 years the compound annual growth rate for Legend Biotech Corp's revenue is 53%. The projected CAGR for the next 3 years is 51%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 268,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.